Ouch: Cipher Maintains Phase III Trial Failure Of Tramadol Will Not Impact NDA
This article was originally published in The Pink Sheet Daily
Executive Summary
Ontario drug maker may have to contend with two other competitors in the synthetic opioid space.
You may also be interested in...
Cipher Seeks Meeting With FDA To Discuss Tramadol “Approvable” Letter
Agency asks for additional efficacy trial for the extended-release opioid analgesic.
Cipher Seeks Meeting With FDA To Discuss Tramadol “Approvable” Letter
Agency asks for additional efficacy trial for the extended-release opioid analgesic.
FDA Needs Six Months To Review Labopharm’s Once-Daily Tramadol
Cipher’s competing tramadol formulation has a user fee date more than a month ahead of the June deadline for Labopharm’s product.